Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
20.03. | Vetoquinol: 2023 Annual Results | 283 | Business Wire | Regulatory News:
Vetoquinol (Paris:VETO):
Annual sales: €529 million (stable at constant exchange rates)
Essentials sales: €313m (+4.5at constant exchange rates)
Net income Group share:... ► Artikel lesen | |
25.01. | France's Vetoquinol drops on profit taking | 1 | Reuters | ||
24.01. | Vetoquinol: Annual Sales 2023: €529 Million | 332 | Business Wire | Annual Sales of Essential products: €313 million (up 4.5% at constant exchange rates)
Regulatory News:
Matthieu Frechin, Chairman and CEO of Vetoquinol (Paris:VETO), said: "In an animal... ► Artikel lesen | |
03.01. | Vetoquinol: 2024 Calendar of Financial Communication | 366 | Business Wire | Regulatory News:
Vetoquinol (Paris:VETO) published its calendar of financial communication for 2024.
January 24, 2024: 2023 Annual revenues (after market)
March 20, 2024: 2023 Annual... ► Artikel lesen | |
26.10.23 | Vetoquinol: Sales 3rd Quarter 2023 | 345 | Business Wire | Q3 Sales: €136m (+5.1% at constant exchange rates)
Q3 Essentials Sales: €81m (+12.2% at constant exchange rates)
Regulatory News:
Matthieu Frechin, Chairman and CEO of Vetoquinol (Paris:VETO)... ► Artikel lesen | |
09.10.23 | Vetoquinol: Announcement of the Availability of the Half-Year Financial Report to June 30, 2023 | 523 | Business Wire | Regulatory News:
Vetoquinol (Paris:VETO) announced today that it has made available to the public and filed with the Autorité des marchés financiers its Half-Year Financial Report to June 30, 2023.... ► Artikel lesen | |
13.09.23 | In 2023, Vetoquinol Celebrates Its 90th Anniversary | 345 | Business Wire | Sustainable development, an integral part of Vetoquinol
Regulatory News:
Vetoquinol's (Paris:VETO) corporate vision underlines its ambition for its entire ecosystem. This vision creates a dynamic... ► Artikel lesen | |
07.09.23 | Vetoquinol: 2023 Half-Year Results | 463 | Business Wire | Sales: €256m (-5.4% as reported)
Essentials products sales: €151m (59% of Group sales)
Net income Group share: €32m (12.6% of sales)
EBITDA*: €54m (20.9% of sales)
Cash-flow generation: €31m
Regulatory... ► Artikel lesen | |
27.07.23 | Vetoquinol, Virbac, and FRONTLINE Among Winners at the 2023 - 2024 World Branding Awards Animalis Edition in Vienna | 597 | Business Wire | The third instalment of the Animalis Edition at the 2023 2024 World Branding Awards welcomed pet and animal brands from around the world, celebrating their achievements as National, Regional, and... ► Artikel lesen | |
19.06.23 | In 2023, Vetoquinol Celebrates Its 90th Anniversary | 338 | Business Wire | Recalling a memorable anniversary day
Regulatory News:
The Vetoquinol (Paris:VETO) saga started 90 years ago in the back office of the Frechin family pharmacy in Lure, Franche Comté (East of... ► Artikel lesen | |
12.06.23 | In 2023, Vetoquinol Celebrates Its 90th Anniversary | 417 | Business Wire | Growth driven by innovation 90 years of innovation
Regulatory News:
Vetoquinol (Paris:VETO):
Ever since the company was founded in 1933, innovation has been a major component of Vetoquinol's... ► Artikel lesen | |
02.06.23 | Dividendenbekanntmachungen (02.06.2023) | 7.293 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADESSO SE DE000A0Z23Q5 - 0,65 EUR ANALOG DEVICES INC US0326541051 0,86 USD 0,7992 EUR ANHUI CONCH CEMENT CO LTD CNE1000001W2 1... ► Artikel lesen | |
25.05.23 | 3rd Generation Appointed Chairman of the Board of Directors of Vetoquinol SA | 423 | Business Wire | Regulatory News:
The Combined General Meeting of Vetoquinol (Paris:VETO) shareholders was held on Thursday 25 May 2023 at the laboratory's head office in Lure (Franche-Comté), chaired by Mr. Etienne... ► Artikel lesen | |
02.05.23 | In 2023, Vetoquinol Celebrates Its 90th Anniversary | 471 | Business Wire | Essential products for the most common needs
Regulatory News:
Vetoquinol (Paris:VETO):
A strategy to meet the needs of its customers.
Vetoquinol is an independent, international animal... ► Artikel lesen | |
24.04.23 | In 2023, Vetoquinol Celebrates Its 90th Anniversary | 336 | Business Wire | The animal health company is firmly established in the world's Top 10.
Regulatory News:
Vetoquinol (Paris:VETO):
A family-owned and independent company
Vetoquinol has managed to preserve... ► Artikel lesen | |
19.04.23 | Vetoquinol: Q1 2023 Sales: €145M | 339 | Business Wire | Q1 2023 Essentials Sales: €87M
Regulatory News:
Matthieu Frechin, Chief Executive Officer of Vetoquinol (Paris:VETO), said: "While we remain aware of the macro-economic uncertainty and the... ► Artikel lesen | |
13.04.23 | Vetoquinol: Availability of the 2022 Universal Registration Document | 469 | Business Wire | Regulatory News:
On 13 April 2023, Vetoquinol (Paris:VETO) filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format).... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BAYER | 28,460 | +0,14 % | Bayer: Neue Allianz mit diesem US-Riesen | Gute News bei Bayer: Der Pharmakonzern hat eine Partnerschaft mit dem US-Riesen Thermo Fisher Scientific angekündigt. Sie zielt darauf ab, schneller und dezentraler diagnostische Tests für präzisionsonkologische... ► Artikel lesen | |
SANOFI | 91,16 | -0,52 % | Minimale Kursveränderung bei Sanofi SA-Aktie (88,97 €) | Der Kurs der der Sanofi SA-Aktie kommt kaum von der Stelle. Das Papier notiert zur Stunde bei 88,97 Euro. Der Kurs der Aktie von Sanofi SA zeigt sich aktuell kaum verändert im Vergleich zu der letzten... ► Artikel lesen | |
BRISTOL-MYERS SQUIBB | 49,450 | +0,61 % | Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes | Company Awards $1.8M in Grants to Eight Organizations in Brazil, India, Thailand and the United Kingdom
Bristol Myers Squibb (NYSE: BMY) today unveiled a $1.8 million initiative to advance health... ► Artikel lesen | |
DERMAPHARM | 32,700 | -4,27 % | EQS-AFR: Dermapharm Holding SE: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Dermapharm Holding SE
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Dermapharm Holding SE: Vorabbekanntmachung... ► Artikel lesen | |
DOCMORRIS | 92,88 | +6,94 % | DocMorris-Aktie nach Zahlen unter Druck - so reagiert Redcare Pharmacy | Die Schweizer DocMorris hat am Donnerstag seine Zahlen für das Geschäftsjahr 2023 vorgelegt und einen aktualisierten Ausblick auf 2024 den Marktteilnehmern an die Hand gegeben. Anleger reagieren verschnupft... ► Artikel lesen | |
INCYTE | 52,78 | +0,04 % | Incyte Corporation: Incyte gibt neue Daten aus Phase-2-Studie zur Untersuchung von Ruxolitinib-Creme (Opzelura) bei Patienten mit leichter bis mittelschwerer Hidradenitis Suppurativa bekannt | Randomisierte Phase-2-Studie erreichte den primären Endpunkt bei Patienten mit Hidradenitis suppurativa (HS) und untermauert Wirksamkeits- und Sicherheitsprofil von Ruxolitinib-Creme Ergebnisse... ► Artikel lesen | |
GREEN THUMB INDUSTRIES | 13,550 | +0,74 % | 3 Things You Need to Know If You Buy Green Thumb Industries Stock Today | ||
TRYP THERAPEUTICS | 0,012 | 0,00 % | Tryp Therapeutics Announces 99.92% Votes Cast by Shareholders in Favor of Arrangement Agreement at Annual General and Special Meeting of Securityholders, and Receipt of Final Order | KELOWNA, BC / ACCESSWIRE / March 12, 2024 / Tryp Therapeutics, Inc. ("Tryp" or the "Company") (CSE:TRYP)(OTCQB:TRYPF) is pleased to announce that the Company's securityholders overwhelmingly approved... ► Artikel lesen | |
OPKO HEALTH | 0,975 | -2,29 % | OPKO Health (OPK) And Entera Bio Announce Data for GLP-2 | ||
BACHEM | 88,20 | +1,82 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 14.03.2024 - 4 | The following instruments on Boerse Frankfurt do have their last trading day on 14.03.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 14.03.2024ISIN NameCH0305285295 VARIA... ► Artikel lesen | |
SELLAS LIFE SCIENCES | 0,939 | -1,78 % | SELLAS Life Sciences Group, Inc.: SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study | - Phase 3 REGAL Study of GPS in AML: Enrollment Completed; Steering Committee Guided Interim Analysis Imminent; IDMC Now Scheduled in Late April - - Phase 2a study of SLS009 in r/r AML: 50% Response... ► Artikel lesen | |
COSMO PHARMACEUTICALS | 71,50 | 0,00 % | Cosmo Pharmaceuticals N.V.: Cosmo Reports Excellent Preliminary Unaudited Full Year 2023 Core Financial Results - Record Guidance for 2024 - Doubles Dividend to 2.00 per Share | Ad hoc announcement pursuant to Art. 53 LR Medtronic deal accounted in 2024, to inject USD 200m cash. FDA approval of GI Genius new enhanced operating system. New GI drug development... ► Artikel lesen | |
ORION | 34,540 | -0,20 % | Dividendenbekanntmachungen (21.03.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AXFOOD AB SE0006993770 4,25 SEK 0,3746 EUR BANCO DE CHILE ADR US0595201064 1,6924 USD 1,5481 EUR BEAZLEY PLC GB00BYQ0JC66 0,142... ► Artikel lesen | |
OXFORD BIOMEDICA | 2,240 | +3,70 % | Oxford BioMedica plc: Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results | Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results Three-year revenue CAGR increased to more than 35%, up from prior guidance of more than 30%Projected FY2024... ► Artikel lesen | |
CITIUS PHARMACEUTICALS | 0,770 | +1,79 % | Citius Pharmaceuticals, Inc.: Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma | FDA assigns Prescription Drug User Fee Act (PDUFA) target action date of August 13, 2024
CRANFORD, N.J., March 18, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq:... ► Artikel lesen |